Advertisement

Drug Investigation

, Volume 2, Issue 3, pp 167–172 | Cite as

Pharmacokinetics and Bioavailability of Tianeptine in the Elderly

  • D. Carlhant
  • J. Le Garrec
  • Y. Guedes
  • C. Salvadori
  • D. Mottier
  • C. Riche
Original Research Article

Summary

A balanced 2-way crossover study involving 12 elderly volunteers was used to determine the pharmacokinetic parameters of the antidepressant tianeptine following a single dose administered by oral and intravenous routes. Pharmacokinetic parameters of metabolite MC5, the C5 side-chain β-oxidation product of tianeptine, were simultaneously determined.

Tianeptine was absorbed rapidly [peak concentration (Cmax) = 261 ± 70 µg/L, and time to Cmax (tmax) = 1.59 ± 0.63 hours] and efficiently, with a bioavailability of 84.6 ± 14.0%.

After intravenous administration, following limited distribution in the tissues [volume of distribution at steady-state (Vdss) = 0.44 ± 0.08 L/kg] tianeptine was rapidly eliminated from the plasma (t½z = 3.1 ± 1.1 hours) mainly through biotransformation [renal clearance (CLR) < 1 ml/min; total clearance (CLT) = 139 ± 28 ml/min].

The MC5 metabolite appeared 0.18 ± 0.04 hours following the beginning of intravenous administration (tmax 2.96 ± 0.95 hours; Cmax = 83 ± 29 µg/L). MC5 was excreted with a terminal half-life of 11.9 ± 8.0 hours; its renal clearance was low (3.1 ± 2.3 ml/min). After oral administration, the pharmacokinetics of the MC5 metabolite remained unchanged, except for tmax which was delayed (tmax = 3.70 ± 0.61 hours).

This study has shown that the bioavailability of tianeptine is high in elderly subjects. Apart from drowsiness observed only following intravenous administration, tianeptine was well tolerated, particularly with regard to cardiovascular effects.

Keywords

Renal Clearance Elderly Subject Drug Invest Tianeptine Mean Absorption Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baccino E, Bressollette L, Mottier D, Mocaër E, Salvadori C, et al. Effects of the antidepressant tianeptine on platelet 5-HT uptake in elderly patients. Abstract. 5th International Meeting on Clinical Pharmacology in Psychiatry, University of Tromso, Norway, June 26–29, p. 28, 1988Google Scholar
  2. Benet LZ, Galeazzi RL. Non-compartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences 68: 1071–1073, 1979PubMedCrossRefGoogle Scholar
  3. Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine. An overview of clinical trials. Clinical Neuropharmacology 11 (Suppl. 2): S74–S82, 1988PubMedGoogle Scholar
  4. Delalleau B, Dulcire C, Le Moine P, Kamoun A. Analysis of the side-effects of tianeptine. Clinical Neuropharmacology 11 (Suppl. 2): S83–S89, 1988PubMedGoogle Scholar
  5. Gomeni R. Pharm: an interactive graphic program for individual and population pharmacokinetic parameter estimation. Computers in Biology and Medicine 14: 25–34, 1984PubMedCrossRefGoogle Scholar
  6. Grislain L, Gele P, Bertrand M, Luijten W, Bromet N, et al. The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. Drug Metabolism and Disposition, in press, 1991Google Scholar
  7. Kato G, Weitsch AF. Neurochemical profile of tianeptine, a new antidepressant drug. Clinical Neuropharmacology 11 (Suppl. 2): S43–S50, 1988PubMedGoogle Scholar
  8. Lôo H, Malka R, Defrance R, Barrucand D, Benard JY, et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 19: 79–85, 1988PubMedCrossRefGoogle Scholar
  9. Lôo H, Deniker P. Position of tianeptine among antidepressive chemotherapies. Clinical Neuropharmacology 11 (Suppl. 2): S97–S102, 1988PubMedGoogle Scholar
  10. Mennini T, Mocaer E, Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedeberg’s Archives of Pharmacology 336: 478–482, 1987PubMedGoogle Scholar
  11. Nicot G, Lachatre G, Gonnet C, Mallon J, Mocaër E. Paired ion extraction and high performance liquid Chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues. Journal of Chromatography Biomedical Applications 381: 115–126, 1986PubMedCrossRefGoogle Scholar
  12. Renaud B, Mocaër E, Weitsch AF, Kato G, Mennini T. Stimulation of serotonin uptake induced by a new antidepressant: Proceedings of the ECNP Constituent meeting, Brussels, May 1987. Pharmacopsychiatry 21: 66, 1988Google Scholar
  13. Royer RJ, Royer-Morrot MJ, Paille F, Barrucand D, Schmitt J, et al. Tianeptine and its main metabolite: pharmacokinetics in chronic alcoholism and cirrhosis. Clinical Pharmacokinetics 16: 186–191, 1989PubMedCrossRefGoogle Scholar
  14. Salvadori C, Ward C, Defrance R, Hopkins R. The pharmacokinetics of the antidepressant tianeptine and its main metabolite: absolute bioavailability and influence of alcohol co-administration. Fundamental and Clinical Pharmacology 4: 115–126, 1990PubMedCrossRefGoogle Scholar
  15. Zini R, Morin D, Salvadori C, Tillement JP. Tianeptine binding to human plasma proteins and plasma from risk populations. British Journal of Clinical Pharmacology 29: 9–18, 1990PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • D. Carlhant
    • 1
  • J. Le Garrec
    • 1
  • Y. Guedes
    • 1
  • C. Salvadori
    • 2
  • D. Mottier
    • 3
  • C. Riche
    • 1
  1. 1.Laboratoire de PharmacologieHôpital MorvanBrestFrance
  2. 2.IRISCourbevoie CédexFrance
  3. 3.Service SebileauHôpital MorvanBrestFrance

Personalised recommendations